Status:
RECRUITING
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Lead Sponsor:
Miro Health
Conditions:
Depression
Mild Cognitive Impairment
Eligibility:
All Genders
60+ years
Brief Summary
Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate...
Eligibility Criteria
Inclusion
- LLD: Age 60 or over; diagnosis of LLD or symptoms consonant with LLD; PHQ-9 score from 15 to 27
- MCI: Age 60 or over; diagnosis of MCI or self-reported insidious onset and continued worsening of cognitive decline; intact activities of daily living
- HC: Age 60 or over
Exclusion
- Age 59 or younger; history of unresolved neurological or psychiatric conditions; current medications known to affect cognition; history of substance abuse; unable to perform activities of daily living; change in employment status due to condition
Key Trial Info
Start Date :
September 8 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
960 Patients enrolled
Trial Details
Trial ID
NCT06011681
Start Date
September 8 2023
End Date
December 31 2024
Last Update
January 22 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Miro Health
Sacramento, California, United States, 95816
2
Miro Health
Miami, Florida, United States, 33070